Lashire Diegue, MD
Psychiatry · Glen Burnie, MDNPI 1245465871
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $591 and has fallen 89.3% since, to $63 in 2025.
Across 62 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$154
- Novo Nordisk$113
- Lilly USA, LLC$108
- Lundbeck LLC$89
- Takeda Pharmaceuticals U.S.A., Inc.$55
- Bausch Health US, LLC$53
- plus $471 from 18 others
What the payments were for
- Food & beverage$1,043100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $154 |
| Novo Nordisk | 8 | $113 |
| Lilly USA, LLC | 6 | $108 |
| Lundbeck LLC | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Bausch Health US, LLC | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Biogen | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| AbbVie | 3 | $43 |
| Amarin Pharma, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Indivior Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Merck | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$1,043 in reported general payments places this provider in the 75th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 15 | $1,192 |
| Bupropion XlBupropion Hcl | 20 | $789 |
| Lorazepam | 30 | $358 |
| Fluoxetine Hcl | 11 | $295 |
| Sertraline Hcl | 15 | $240 |
| Clonazepam | 34 | $232 |
| Buspirone Hcl | 18 | $205 |
| Aripiprazole | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glen Burnie
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.